Cancer Treatment Updates
Study identifies potential approach to treat severe respiratory distress in patients with COVID-19
June 5th, 2020
As described in an NCI Media Availability, early data from a clinical study suggest that treatment with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
May 26th, 2020
In an NCI study, an alternative treatment regimen called dose-adjusted EPOCH-R that is less toxic than standard dose-intensive chemotherapy was highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status.Higher daily step count linked with lower all-cause mortality
March 24th, 2020
In a new study, higher daily step counts were associated with lower mortality risk from all causes. Researchers found that the number of steps taken each day, but not the intensity of the stepping, had a strong association with mortality.NCI statement on clinical trials during COVID-19 pandemic
March 19th, 2020
Statement from the National Cancer Institute providing information regarding treatment of cancer patients and participation in clinical trials during the COVID-19 pandemic.NCI study provides genetic insights into osteosarcoma in children
March 19th, 2020
A new study offers insight into genetic alterations associated with osteosarcoma, the most common bone tumor of children and adolescents, and the findings have implications for genetic testing of children with osteosarcoma and their families.In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1
March 18th, 2020
An NCI clinical trial finds the drug selumetinib improves outcomes for children with neurofibromatosis type 1 (NF1), shrinking inoperable tumors called plexiform neurofibromas, reducing pain, and improving function and overall quality of life.Annual Report to the Nation: Cancer death rates continue to decline
March 12th, 2020
The 2020 Annual Report to the Nation on the Status of Cancer finds overall cancer death rates continue to decline in the United States for all cancer sites combined. A companion study looked at Healthy People 2020 targets for four common cancers.Testing with combined biopsy method improves prostate cancer diagnosis in NCI study
March 4th, 2020
Testing for prostate cancer with a combined biopsy method led to more accurate diagnosis and prediction of the course of the disease in an NCI study. The method is poised to reduce the risk of prostate cancer overtreatment and undertreatment.Immunotherapy drug improves outcomes for some children with relapsed leukemia
December 10th, 2019
For children and young adults with certain relapsed B-cell acute lymphoblastic leukemia (B-ALL), the immunotherapy drug blinatumomab is superior to standard chemotherapy, an NCI-sponsored Children’s Oncology Group trial shows.Study quantifies impact of NCI-sponsored trials on clinical cancer care
September 18th, 2019
Nearly half of phase 3 cancer clinical trials carried out by the NCI-sponsored SWOG Cancer Research Network were associated with clinical care guidelines or new drug approvals, a study in JAMA Network Open shows.